COVID-19 Impact on CRISPR/Cas9 Market, Global Research Reports 2020-2021

Published On: Jun 2020

Format: PDF

Publisher: QY Research

Pages: 106

Report ID: 461744

This report covers market size and forecasts of CRISPR/Cas9, including the following market information:
Global CRISPR/Cas9 Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global CRISPR/Cas9 Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global CRISPR/Cas9 Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global CRISPR/Cas9 Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market players
Major competitors identified in this market include Caribou Biosciences, Integrated DNA Technologies (IDT), CRISPR Therapeutics, Merck, Mirus Bio, Editas Medicine, Takara Bio, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, Agilent Technologies, Cellecta, GenScript, GeneCopoeia, Synthego, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Genome Editing
Genetic engineering
gRNA Database/Gene Librar
CRISPR Plasmid
Human Stem Cells
Genetically Modified Organisms/Crops
Cell Line Engineering

Based on the Application:
Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research and Development Institutes

1.1 Research Scope<br />    1.2 Market Segmentation<br />    1.3 Research Objectives<br />    1.4 Research Methodology<br />        1.4.1 Research Process<br />        1.4.2 Data Triangulation<br />        1.4.3 Research Approach<br />        1.4.4 Base Year<br />    1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth<br />        1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections<br />        1.5.2 Covid-19 Impact: Commodity Prices Indices<br />        1.5.3 Covid-19 Impact: Global Major Government Policy<br />    1.6 The Covid-19 Impact on CRISPR/Cas9 Industry<br />    1.7 COVID-19 Impact: CRISPR/Cas9 Market Trends<br /><br />2 Global CRISPR/Cas9 Quarterly Market Size Analysis<br />    2.1 CRISPR/Cas9 Business Impact Assessment - COVID-19<br />        2.1.1 Global CRISPR/Cas9 Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026<br />    2.2 Global CRISPR/Cas9 Quarterly Market Size 2020-2021<br />    2.3 COVID-19-Driven Market Dynamics and Factor Analysis<br />        2.3.1 Drivers<br />        2.3.2 Restraints<br />        2.3.3 Opportunities<br />        2.3.4 Challenges<br /><br />3 Quarterly Competitive Assessment, 2020<br />    3.1 By Players, Global CRISPR/Cas9 Quarterly Market Size, 2019 VS 2020<br />    3.2 By Players, CRISPR/Cas9 Headquarters and Area Served<br />    3.3 Date of Key Players Enter into CRISPR/Cas9 Market<br />    3.4 Key Players CRISPR/Cas9 Product Offered<br />    3.5 Mergers & Acquisitions, Expansion Plans<br /><br />4 Impact of Covid-19 on CRISPR/Cas9 Segments, By Type<br />    4.1 Introduction<br />        1.4.1 Genome Editing<br />        1.4.2 Genetic engineering<br />        1.4.3 gRNA Database/Gene Librar<br />        1.4.4 CRISPR Plasmid<br />        1.4.5 Human Stem Cells<br />        1.4.6 Genetically Modified Organisms/Crops<br />        1.4.7 Cell Line Engineering<br />    4.2 By Type, Global CRISPR/Cas9 Market Size, 2019-2021<br /><br />5 Impact of Covid-19 on CRISPR/Cas9 Segments, By Application<br />    5.1 Overview<br />        5.5.1 Biotechnology Companies<br />        5.5.2 Pharmaceutical Companies<br />        5.5.3 Academic Institutes<br />        5.5.4 Research and Development Institutes<br />    5.2 By Application, Global CRISPR/Cas9 Market Size, 2019-2021<br />        5.2.1 By Application, Global CRISPR/Cas9 Market Size by Application, 2019-2021<br /><br />6 Geographic Analysis<br />    6.1 Introduction<br />    6.2 North America<br />        6.2.1 Macroeconomic Indicators of US<br />        6.2.2 US<br />        6.2.3 Canada<br />    6.3 Europe<br />        6.3.1 Macroeconomic Indicators of Europe<br />        6.3.2 Germany<br />        6.3.3 France<br />        6.3.4 UK<br />        6.3.5 Italy<br />    6.4 Asia-Pacific<br />        6.4.1 Macroeconomic Indicators of Asia-Pacific<br />        6.4.2 China<br />        6.4.3 Japan<br />        6.4.4 South Korea<br />        6.4.5 India<br />        6.4.6 ASEAN<br />    6.5 Rest of World<br />        6.5.1 Latin America<br />        6.5.2 Middle East and Africa<br /><br />7 Company Profiles<br />    7.1 Caribou Biosciences<br />        7.1.1 Caribou Biosciences Business Overview<br />        7.1.2 Caribou Biosciences CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.1.3 Caribou Biosciences CRISPR/Cas9 Product Introduction<br />        7.1.4 Caribou Biosciences Response to COVID-19 and Related Developments<br />    7.2 Integrated DNA Technologies (IDT)<br />        7.2.1 Integrated DNA Technologies (IDT) Business Overview<br />        7.2.2 Integrated DNA Technologies (IDT) CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.2.3 Integrated DNA Technologies (IDT) CRISPR/Cas9 Product Introduction<br />        7.2.4 Integrated DNA Technologies (IDT) Response to COVID-19 and Related Developments<br />    7.3 CRISPR Therapeutics<br />        7.3.1 CRISPR Therapeutics Business Overview<br />        7.3.2 CRISPR Therapeutics CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.3.3 CRISPR Therapeutics CRISPR/Cas9 Product Introduction<br />        7.3.4 CRISPR Therapeutics Response to COVID-19 and Related Developments<br />    7.4 Merck<br />        7.4.1 Merck Business Overview<br />        7.4.2 Merck CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.4.3 Merck CRISPR/Cas9 Product Introduction<br />        7.4.4 Merck Response to COVID-19 and Related Developments<br />    7.5 Mirus Bio<br />        7.5.1 Mirus Bio Business Overview<br />        7.5.2 Mirus Bio CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.5.3 Mirus Bio CRISPR/Cas9 Product Introduction<br />        7.5.4 Mirus Bio Response to COVID-19 and Related Developments<br />    7.6 Editas Medicine<br />        7.6.1 Editas Medicine Business Overview<br />        7.6.2 Editas Medicine CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.6.3 Editas Medicine CRISPR/Cas9 Product Introduction<br />        7.6.4 Editas Medicine Response to COVID-19 and Related Developments<br />    7.7 Takara Bio<br />        7.7.1 Takara Bio Business Overview<br />        7.7.2 Takara Bio CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.7.3 Takara Bio CRISPR/Cas9 Product Introduction<br />        7.7.4 Takara Bio Response to COVID-19 and Related Developments<br />    7.8 Thermo Fisher Scientific<br />        7.8.1 Thermo Fisher Scientific Business Overview<br />        7.8.2 Thermo Fisher Scientific CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.8.3 Thermo Fisher Scientific CRISPR/Cas9 Product Introduction<br />        7.8.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments<br />    7.9 Horizon Discovery Group<br />        7.9.1 Horizon Discovery Group Business Overview<br />        7.9.2 Horizon Discovery Group CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.9.3 Horizon Discovery Group CRISPR/Cas9 Product Introduction<br />        7.9.4 Horizon Discovery Group Response to COVID-19 and Related Developments<br />    7.10 Intellia Therapeutics<br />        7.10.1 Intellia Therapeutics Business Overview<br />        7.10.2 Intellia Therapeutics CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.10.3 Intellia Therapeutics CRISPR/Cas9 Product Introduction<br />        7.10.4 Intellia Therapeutics Response to COVID-19 and Related Developments<br />    7.11 Agilent Technologies<br />        7.11.1 Agilent Technologies Business Overview<br />        7.11.2 Agilent Technologies CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.11.3 Agilent Technologies CRISPR/Cas9 Product Introduction<br />        7.11.4 Agilent Technologies Response to COVID-19 and Related Developments<br />    7.12 Cellecta<br />        7.12.1 Cellecta Business Overview<br />        7.12.2 Cellecta CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.12.3 Cellecta CRISPR/Cas9 Product Introduction<br />        7.12.4 Cellecta Response to COVID-19 and Related Developments<br />    7.13 GenScript<br />        7.13.1 GenScript Business Overview<br />        7.13.2 GenScript CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.13.3 GenScript CRISPR/Cas9 Product Introduction<br />        7.13.4 GenScript Response to COVID-19 and Related Developments<br />    7.14 GeneCopoeia<br />        7.14.1 GeneCopoeia Business Overview<br />        7.14.2 GeneCopoeia CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.14.3 GeneCopoeia CRISPR/Cas9 Product Introduction<br />        7.14.4 GeneCopoeia Response to COVID-19 and Related Developments<br />    7.15 Synthego<br />        7.15.1 Synthego Business Overview<br />        7.15.2 Synthego CRISPR/Cas9 Quarterly Revenue, 2020<br />        7.15.3 Synthego CRISPR/Cas9 Product Introduction<br />        7.15.4 Synthego Response to COVID-19 and Related Developments<br /><br />8 Key Findings<br /><br />9 Appendix<br />    9.1 About US<br />    9.2 Disclaimer<br />